上海市徐汇区淮海中路 1010 号嘉华中心 45 层 邮编：200031 电话：(86-21) 5404 9930 传真：(86-21) 5404 9931 2．本所律师无法对网络投票过程进行见证，参与本次会议网络投票的股东 资格、网络投票结果均由深圳证券交易所（以下简称"深交所"）交易系统和互 联网投票系统予以认证； 北京市竞天公诚律师事务所上海分所 关于云南沃森生物技术股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：云南沃森生物技术股份有限公司（贵公司） 北京市竞天公诚律师事务所上海分所（以下简称"本所"）接受贵公司的委 托，指派律师出席并见证贵公司 2025 年第一次临时股东大会（以下简称"本次 会议"）。 本所律师根据《中华人民共和国公司法》（以下简称《公司法》）、《中华 人民共和国证券法》（以下简称《证券法》）、《上市公司股东会规则》（以下 简称《股东会规则》）、《律师事务所从事证券法律业务管理办法》（以下简称 《证券法律业务管理办法》）、《律师事务所证券法律业务执业规则（试行）》 （以下简称《证券法律业务执业规则》）等相关法律、行政法规、规章、规范性 文件及《云南沃森生物技术股份有 ...

公告显示，玉溪沃森为沃森生物重要的核心子公司。2024年及2025年前三季度，玉溪沃森营收分别约 26.64亿元、16.82亿元，净利润分别约2.54亿元、2.69亿元。 沃森生物方面表示，本次受让玉溪沃森股权将进一步增加公司对玉溪沃森的持股比例，增强对玉溪沃森 的控制力，提高玉溪沃森决策效率，同时有利于进一步提升公司的收入和利润水平，增厚公司的经营业 绩。 近日，云南沃森生物技术股份有限公司（300142.SZ，以下简称"沃森生物"）公告拟以合计约20亿元受 让玉溪沃森生物技术有限公司（以下简称"玉溪沃森"）约13.78%股权。交易完成后，沃森生物对玉溪沃 森的持股比例将增至约92%。 截至2025年9月30日，玉溪沃森资产总额约69.62亿元，负债总额约28.38亿元，净资产约41.24亿元，其 总资产占沃森生物总资产的比例超过一半。 从业务实质来看，玉溪沃森是沃森生物生产能力的绝对核心。 沃森生物方面表示，玉溪沃森经营状况和财务状况较好，是公司收入和利润的最主要来源，也是公司国 际化业务和新业务拓展的重要支撑，发展前景广阔。2024年，公司海外业务收入达5.7亿元（其中产品 销售收入3.76亿元，技术服 ...

Core Viewpoint - Watson Bio has received approval for a clinical trial of a freeze-dried mRNA vaccine for herpes zoster, developed in collaboration with several partners [2] Company Summary - Watson Bio's subsidiary, Beijing Watson Innovation Biotechnology Co., Ltd., along with Yunnan Vaccine Laboratory Co., Ltd. and Yuxi Watson Biotechnology Co., Ltd., is involved in the development of the mRNA vaccine [2] - The vaccine development is a joint effort with Fudan University and Shanghai Blue Magpie Biomedical Co., Ltd. [2] Industry Summary - The approval from the National Medical Products Administration marks a significant step in the advancement of mRNA vaccine technology in the field of infectious diseases [2]

Core Viewpoint - Watson Bio (300142.SZ) announced that its subsidiary, Beijing Watson Innovation Biotechnology Co., Ltd., along with Yunnan Vaccine Laboratory Co., Ltd. and Yuxi Watson Biotechnology Co., Ltd., has jointly developed and applied for clinical trials of a lyophilized varicella-zoster virus mRNA vaccine in collaboration with Fudan University and Shanghai Blue Magpie Biopharmaceutical Co., Ltd. The vaccine has recently received the Clinical Trial Approval Notification from the National Medical Products Administration, allowing the commencement of clinical trials aimed at preventing shingles [1]. Group 1 - Watson Bio's subsidiary has received approval for clinical trials of a new mRNA vaccine targeting shingles [1] - The vaccine development involves collaboration with notable institutions including Fudan University and Shanghai Blue Magpie Biopharmaceutical Co., Ltd. [1] - The approval indicates that the vaccine meets the necessary requirements for drug registration as of September 18, 2025 [1]

Core Viewpoint - Watson Bio (300142) has recently received approval from the National Medical Products Administration for a clinical trial of a freeze-dried varicella-zoster virus mRNA vaccine, developed in collaboration with several partners [1] Group 1 - The clinical trial approval was granted for a vaccine developed by Watson Bio's subsidiary, Beijing Watson Innovation Biotechnology Co., Ltd., in partnership with Yunnan Vaccine Laboratory Co., Ltd., Yuxi Watson Biotechnology Co., Ltd., Fudan University, and Shanghai Blue Magpie Biomedical Co., Ltd. [1]

Core Viewpoint - Watson Bio's subsidiary has received approval for clinical trials of a freeze-dried mRNA vaccine for herpes zoster from the National Medical Products Administration of China [1] Group 1: Company Developments - Watson Bio, along with Fudan University and Shanghai Bluebird Biomedicine, has jointly developed and applied for clinical trials of the mRNA vaccine [1] - The vaccine aims to stimulate the immune system to produce immunity against the herpes zoster virus for prevention purposes [1] Group 2: Regulatory Approval - The clinical trial approval notice was issued under the registration categories of preventive biological products [1] - The approval was based on compliance with the relevant requirements of the Drug Administration Law and Vaccine Administration Law of the People's Republic of China [1]

Core Viewpoint - Watson Bio has received approval from the National Medical Products Administration for clinical trials of a freeze-dried varicella-zoster virus mRNA vaccine, developed in collaboration with Fudan University and Shanghai Blue Magpie Biopharmaceutical Co., Ltd [1] Group 1: Company Developments - Watson Bio's subsidiary, Beijing Watson Innovation Biotechnology Co., Ltd., along with Yunnan Vaccine Laboratory Co., Ltd. and Yuxi Watson Biotechnology Co., Ltd., is involved in the joint development of the mRNA vaccine [1] - The clinical trial approval notification number is 2025LP03354; 2025LP03355, and the vaccine is classified as a preventive biological product [1] - The approval indicates that the vaccine meets the requirements for drug registration as per Chinese regulations, allowing for clinical trials aimed at preventing shingles [1] Group 2: Financial Performance - For the first half of 2025, Watson Bio's revenue composition is as follows: self-developed vaccines account for 94.82%, intermediate product revenue 4.67%, other business 0.26%, and service revenue 0.24% [1] - As of the report date, Watson Bio's market capitalization stands at 18.1 billion yuan [1]

Core Viewpoint - Watson Bio (300142.SZ) announced that its subsidiaries have received approval from the National Medical Products Administration for a clinical trial of a freeze-dried mRNA vaccine for herpes zoster, developed in collaboration with Fudan University and Shanghai Blue Magpie Biopharmaceutical Co., Ltd [1] Group 1 - The clinical trial approval was granted for the freeze-dried herpes zoster virus mRNA vaccine, which is intended for the prevention of herpes zoster [1] - The vaccine application was reviewed and found to meet the requirements for drug registration, with the trial set to commence [1] - The approval notification was issued on September 18, 2025, indicating a timeline for the clinical trial process [1]

证券代码：300142 证券简称：沃森生物 公告编号：2025-077 标准后，方能向国家药品监督管理局申请药品上市许可。临床研究期间，疫苗的 临床试验进度和研究结果等均具有一定的不确定性。敬请广大投资者谨慎决策， 注意投资风险。 特此公告。 云南沃森生物技术股份有限公司 云南沃森生物技术股份有限公司 关于子公司收到冻干带状疱疹病毒 mRNA 疫苗《药物临床试 验批准通知书》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 由云南沃森生物技术股份有限公司（以下简称"公司"或"沃森生物"）子 公司北京沃森创新生物技术有限公司、云南疫苗实验室有限公司、玉溪沃森生物 技术有限公司与复旦大学、上海蓝鹊生物医药有限公司（以下简称"蓝鹊生物"） 联合研发并共同申请临床试验的冻干带状疱疹病毒 mRNA 疫苗，于近日获得国家 药品监督管理局签发的《药物临床试验批准通知书》。通知书编号为： 2025LP03354；2025LP03355。注册分类：预防用生物制品。审批结论：根据《中 华人民共和国药品管理法》《中华人民共和国疫苗管理法》及有关规定，经审查， 2025年9月1 ...

证券代码：300142 证券简称：沃森生物 公告编号：2025-078 云南沃森生物技术股份有限公司 关于召开2025年第一次临时股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 经云南沃森生物技术股份有限公司（以下简称"公司"）第五届董事会第 三十三次会议审议通过，决定于 2025 年 12 月 19 日（星期五）召开公司 2025 年第一次临时股东大会。本次股东大会的会议通知已于 2025 年 11 月 29 日公布 于中国证监会指定的创业板信息披露网站巨潮资讯网。本次股东大会将采用现 场会议与网络投票相结合的方式召开。现就本次股东大会的相关事宜再次提示 公告如下： 一、召开会议的基本情况 1、股东大会届次：2025 年第一次临时股东大会 2、股东大会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易 所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创 业板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司 章程》的有关规定。 4、会议时间： （1）现场会议时间：20 ...